Technology
Choose a subcategory:
For additional information about Nabi Biopharmaceuticals, please visit www.nabi. com CONTACT: Nabi Biopharmaceuticals Investor Relations 301-770- 3099 www.nabi. com
SOSUA BAY, Dominican Republic, March 11, 2010 ( GLOBE NEWSWIRE)- Proton Laboratories, Inc. President & CEO, Armando Casciati, announced today that the Company's updated information and disclosure statement has been filed on www.pinksheets.
HASBROUCK HEIGHTS, N.J., March 11, 2010 ( GLOBE NEWSWIRE)- Nymox Pharmaceutical Corporation announced today its financial results for the year ended December 31, 2009.
Generex Receives Positive Responses From Independent Physicians and Nurse Practitioners in Recent Fo
Generex announced in September 2009 that the USFDA has granted approval for the treatment use of Generex Oral-lyn ( TM) in patients with Type 1 or Type 2 diabetes mellitus under the FDA's expanded access Treatment IND program.
The shares and warrants offered in the private placement and the shares issuable upon the exercise of the warrants have not been registered under the Securities Act of 1933, as amended, or state securities laws, and may not be offered or so
These forward-looking statements include without limitation, statements regarding, the timing, progress and anticipated results of regulatory processes, including potential NDA filings and other regulatory submissions relating to Marqibo, a
Orchid Cellmark Inc. and Subsidiaries Condensed Consolidated Statements of Operations Three months and twelve months ended December 31, 2009 and 2008 ( In thousands, except per share data) ( Unaudited) Three months ended Years ended Decembe
To read the entire report visit: http:// www.investorsoup. com/lp/ EXAS See what investors say about EXAS at penny stock forum InvestorSoup. com is a small-cap research and investment commentary provider.
The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including uncertainties with respect to the fact that additional tri
In particular, the risks and uncertainties include, among other things: risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured; the risk that we will not achieve the anticipated benefits of
2009 Highlights Droxidopa:- Initiated Phase II trial of Droxidopa in fibromyalgia- Reported statistically significant reduction ( 87.5%) in the number of patients requiring early termination of hemodialysis sessions in Phase II trial of Dro
COMBIMATRIX CORPORATION CONSOLIDATED SUMMARY FINANCIAL INFORMATION ( In thousands, except share and per share information) ( Unaudited) CONSOLIDATED BALANCE SHEET INFORMATION: December December 31, 31, 2009 2008 Total cash, cash equivalents